We expected to detect frequent mutations of KRAS, which frequently (50–60%) occur in gallbladder and biliary tract cancers of patients with pancreaticobiliary maljunction because of regurgitation of bile and pancreatic fluid30. This evidence concerns the gene KRAS and biliary tract cancer.